{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-24-000093","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2024-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.874095+00:00","generated_at":"2026-05-29T19:05:32.113536+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Barinthus Bio promotes Geoffrey Lynn to CSO; Nadège Pelletier steps down","bullets":["Nadège Pelletier to step down as Chief Scientific Officer effective Feb 2, 2025; she served since early 2023.","Geoffrey Lynn, M.D., Ph.D. promoted to CSO effective Dec 1, 2024; he is co-inventor of SNAP-TI technology.","Lynn previously led Avidea Technologies (acquired by Barinthus in 2021) and holds M.D. from Johns Hopkins, D.Phil. from Oxford.","Company highlights pipeline progress: VTP-300 in chronic hepatitis B, VTP-1000 (SNAP-TI) in Phase 1 for celiac disease.","Transition expected to be smooth; Pelletier will remain until responsibilities transitioned."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-24-000093","json":"https://secwatch.observer/filing/0001828185-24-000093.json","markdown":"https://secwatch.observer/filing/0001828185-24-000093.md","text":"https://secwatch.observer/filing/0001828185-24-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000093/0001828185-24-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000093/brns-20241125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T19:05:32.113536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71c9f1839d","claim":"Nadège Pelletier departed as Chief Scientific Officer at Barinthus Biotherapeutics plc..","evidence_excerpt":"On November 25, 2024, Nadège Pelletier, Ph.D., notified Barinthus Biotherapeutics plc (the \"Company\") that she will step down as Chief Scientific Officer of the Company effective February 2, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000093/0001828185-24-000093-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"step down"},{"label":"Role","value":"Chief Scientific Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}